Carregant...
Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone acetate and enzalutamide), chemotherapeutics (doceta...
Guardat en:
| Publicat a: | Ther Adv Urol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4580096/ https://ncbi.nlm.nih.gov/pubmed/26445599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287215592288 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|